REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN) from its SEC filings: 2025 revenue $14.3 billion (+1% vs the year before), net margin 31%, free cash flow $5.0 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $14.3 billion |
| Revenue growth | +1% |
| Net income | $4.5 billion |
| Net margin | 31.4% |
| Free cash flow | $5.0 billion |
| Diluted EPS | $41.48 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +17% |
| Cash | $2.5 billion |
| Long-term debt | $2.0 billion |
| Share count, 1 year | +5% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-26. Education only, not financial advice.